Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMI21
- Development stage
- Preclinical
- Lead developer
- Precision Molecular
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**PMI21** is an investigational targeted alpha therapy developed by Precision Molecular Inc., consisting of an astatine-211 (211At)-labeled small molecule inhibitor of prostate-specific membrane antigen (PSMA). PSMA is minimally expressed in normal prostate tissue but highly overexpressed on prostate cancer cells, enabling selective tumor targeting. The PSMA-binding and 211At-labeling moieties are optimized for high tumor uptake, rapid clearance from normal tissues, and potent alpha-particle emission that delivers high-energy, short-range radiation to kill cancer cells while minimizing off-target toxicity compared to beta-emitters or multi-alpha emitters like actinium-225. PMI21 is licensed from Johns Hopkins University and supplied with 211At via Ionetix, with plans for clinical trials in metastatic prostate cancer.[1][2][3]
- Other names
- PMI-21PMI21PMI 21ZA-001ZA001ZA 001
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PMI21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMI21.